Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA FY 1991 BUDGET REQUEST ASSUMES USER FEE REVENUES

Executive Summary

FDA FY 1991 BUDGET REQUEST ASSUMES USER FEE REVENUES of at least $ 144 mil., according to correspondence between HHS and the Office of Management and Budget in preparation for next year's budget. In a Nov. 27 letter to OMB Director Richard Darman, HHS Secretary Sullivan said FDA's fiscal year (FY) 1991 "budget request is $ 43 mil. in budget authority below that provided by the Congress for FY 1990, with the remainder of our budget request for FDA being $ 144 mil. in user fees, which was accepted by OMB." Sullivan was replying to OMB's Nov. 20 "passback" review of the department's budget request. The department has requested a total FY 1991 budget authority of $ 632 mil. for FDA. If more than $ 144 mil. in user fee income is assumed, the Bush Administration will ask Congress for less than $ 488 mil. in FDA appropriations. * Noting that the Administration has plans for "revitalizing FDA," Sullivan asked OMB "to restore FDA to the original level sought in September of $ 632 mil." The total "assumes a substantial contribution by industry through $ 144 mil. in user fee support," the letter states. The Administration is expected to ask for more than $ 144 mil. in user fees. On its face, the $ 632 mil. budget authority for fiscal 1991 would be about $ 38 mil. more than the Congressional budget package for fiscal 1990 which gives FDA $ 594.4 mil. and does not include user fees. On Nov. 21, President Bush signed FDA's budget appropriation for fiscal 1990: $ 560.3 mil. for salaries and expenses and $ 8.35 mil. for buildings and facilities. Another $ 25.6 mil. has been set aside for rent. However, FDA appropriations in the current fiscal year will be reduced by a 1.4% across the board budget sequestration that will put FDA's fiscal 1990 budget closer to $ 585 mil. In his letter to Darman, Sullivan suggests that an increase in total FDA funding in fiscal 1991 is needed in large part to provide for generic drug industry regulation. Sullivan pointed out the Administration has agreed "to improve oversight of generic drug approval because of the high risk associated with this activity," and the FDA budget request would "provide the resources to control these risks." The Administration is considering a request for a supplemental budget for FY 1990 in order to enhance funding for generic drug regulation. "We are committed to the revitalization of FDA," Sullivan declared. "Improvement in the quality and integrity of the entire regulatory process, especially generic drugs, requires an infusion of new resources in both FY 1990 and FY 1991." Sullivan noted that HHS is lowering its budget request for the Health Care Financing Administration in the wake of the congressional repeal of the Catastrophic Care Act. For HCFA, the letter states, "we are reducing our original 1991 request by $ 562 mil. due to the repeal of the" Medicare program. OMB had hoped to resolve appeals from all departments and agencies by Dec. 8. The agency has now moved the appeal deadline back to Dec. 14. Remaining areas of contention are expected to be ironed out between department heads and President Bush in face-to-face meetings.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel